Group 1 - The Hong Kong Stock Exchange (HKEX) currently has approximately 280 companies that have submitted A1 listing applications, with about half being technology companies and around 30 being chip-related companies [1] - In recent years, there has been a significant increase in hardware and hard technology companies listing in Hong Kong, compared to earlier years when most were software companies [4] - In 2023, HKEX introduced Chapter 18C to support specialized technology companies in sectors such as semiconductors, robotics and automation, and artificial intelligence to list in Hong Kong [4] Group 2 - In May 2023, the Hong Kong Securities and Futures Commission and HKEX jointly launched the "Tech Company Fast Track," establishing a dedicated team to provide listing guidance for specialized technology companies under Chapter 18C, allowing them to submit materials confidentially [5] - The dedicated consultation service channel enables quality chip companies to seek expert advice before listing [5] - HKEX will regularly update the themes covered under Chapter 18C based on the latest technological trends [5]

Core Viewpoint - Hong Kong Stock Exchange (HKEX) is set to launch the Hang Seng Biotechnology Index Futures on November 28, 2025, aiming to enhance its derivatives product ecosystem and provide investors with effective risk management tools in the rapidly growing biotechnology sector [1][1]. Group 1: Product Launch - The new futures contract will be based on the Hang Seng Biotechnology Index, focusing on one of the fastest-growing and most dynamic sectors [1]. - The launch is contingent upon regulatory approval, indicating a structured approach to introducing new financial products [1]. Group 2: Market Context - The biotechnology industry is currently one of the hottest sectors in the capital markets, driven by technological innovation and significant global healthcare demand [1]. - Since the introduction of the listing regime reform in 2018, the biotechnology and healthcare sectors have become the fastest-growing industries on the Hong Kong capital market, with over 260 biotechnology and healthcare companies listed, totaling a market capitalization of over HKD 4.8 trillion, which is four times the approximately HKD 1.2 trillion at the end of 2018 [1][1].

香港本地股方面，长实集团跌2.13%，收报36.78港元；新鸿基地产跌1.45%，收报95.35港元；恒基 地产涨0.22%，收报27.46港元。 中资金融股方面，中国银行涨0.48%，收报4.2港元；建设银行涨2.32%，收报7.49港元；工商银行 涨1.77%，收报5.76港元；中国平安涨1.05%，收报53港元；中国人寿涨1.58%，收报21.92港元。 石油石化股方面，中国石油化工股份跌1.46%，收报4.04港元；中国石油股份跌1.23%，收报7.21港 元；中国海洋石油跌1.11%，收报18.63港元。 责任编辑：袁浩 新华社香港10月14日电 香港恒生指数14日跌448.13点，跌幅1.73%，收报25441.35点。全日主板成 交3989.1亿港元。 国企指数跌143.38点，收报9079.16点，跌幅1.55%。恒生科技指数跌222.25点，收报5923.26点，跌 幅3.62%。 蓝筹股方面，腾讯控股跌2.82%，收报621港元；香港交易所跌2.96%，收报420港元；中国移动跌 0.24%，收报84.7港元；汇丰控股跌0.68%，收报101.9港元。 ...

Core Viewpoint - Hong Kong Stock Exchange (HKEX) shares have dropped over 3%, currently trading at HKD 419.8, with a trading volume of HKD 4.454 billion, amid escalating trade tensions impacting market sentiment [1] Market Sentiment and Trading Environment - The recent escalation in trade tensions has led to a decline in investor risk appetite, resulting in a valuation correction for Hong Kong stocks [1] - Huatai Securities indicates that the key to short-term trading direction lies in whether market sentiment has reached an extreme point, suggesting there is still room for further release in market sentiment indicators [1] - The evolution of trade friction issues is expected to have significant variance over the next one to two weeks, indicating that high volatility may persist [1] Upcoming Earnings and Forecasts - HKEX is set to announce its third-quarter results on November 5, with UBS predicting a year-on-year revenue and net profit growth of 43% and 53%, respectively, reaching HKD 7.7 billion and HKD 4.8 billion, marking new highs [1] - UBS's forecasts exceed general market expectations by 8% and 11% [1] - Given the current market atmosphere and increased participation from southbound capital, UBS has raised its average daily trading volume forecast for HKEX from 9% to 16% for 2025 to 2027, and adjusted its earnings per share forecast upward by 7% to 12%, setting a target price of HKD 485 with a "neutral" rating [1]

智通财经APP获悉，港交所(00388)再跌超3%，截至发稿，跌3%，报419.8港元，成交额44.54亿港元。 消息面上，上周五贸易战升级态势超出市场，投资者风险偏好下降带动港股估值回调。华泰证券表示， 短期操作方向判断的关键在于市场情绪是否已经较为极致，从资金面和港股情绪指标看还有进一步释放 空间，贸易摩擦问题未来一两周演进路径方差较大，高波动行情或仍将持续。 值得注意的是，港交所将于11月5日公布第三季度业绩。瑞银预测季度收入及纯利将同比增长43%及 53%，达到77亿及48亿元，再创新高。该行预测较市场普遍预期高出8%及11%。考虑到市场气氛情况及 南下资金参与度上升，瑞银将港交所2025至2027年日均成交额预测上调9%至16%，并将港交所每股盈 利预测上调7%至12%，目标价485港元，评级"中性"。 ...

Core Viewpoint - Hong Kong Stock Exchange plans to launch the Hang Seng Biotechnology Index Futures, set to begin trading on November 28, 2025, providing investors with precise risk management tools in the rapidly growing biotechnology sector [1] Group 1: Product Launch - The new futures contract will be based on the Hang Seng Biotechnology Index, which tracks the performance of the 30 largest biotechnology, pharmaceutical, and medical device companies listed in Hong Kong that are eligible for Stock Connect trading [1] - The introduction of this futures product aims to enhance investment channels in the biotechnology industry and provide effective hedging tools [1] Group 2: Market Context - The biotechnology sector is currently one of the hottest industries in the capital markets, driven by technological innovation and significant global healthcare demand [1] - Since the listing reform in 2018, biotechnology and healthcare have become one of the fastest-growing sectors in the Hong Kong capital market, with over 260 biotechnology and healthcare companies listed, totaling a market capitalization of over HKD 4.8 trillion, which is four times the approximately HKD 1.2 trillion at the end of 2018 [1] Group 3: Strategic Goals - The launch of the Hang Seng Biotechnology Index Futures is expected to further solidify Hong Kong's position as a leading center for derivative trading and risk management in Asia [1] - The Hong Kong Stock Exchange will continue to promote market development, increase market depth, and diversify product offerings to meet the evolving needs of global investors [1]

Core Viewpoints - The Hong Kong Stock Exchange (HKEX) reported a market capitalization of HKD 49.85 trillion as of September 2025, reflecting a month-on-month increase of 7.01% and a year-on-year increase of 35.03% [1] - The average daily trading (ADT) for Q3 reached HKD 286.36 billion, showing a year-on-year growth of 144.80% and a month-on-month increase of 20.48% [1] - In Q3 2025, 28 new companies were listed, raising a total of HKD 478.38 billion, which is a 33.75% increase year-on-year [2] - The derivatives market showed positive growth, with average daily trading volume for futures and options reaching 165 million contracts, up 9.28% year-on-year [3] Market Activity - Southbound capital inflow totaled HKD 399.99 billion from July to September 2025, a year-on-year increase of 230.22%, significantly boosting market activity [2] - The average daily trading volume for the Hong Kong Stock Connect southbound trading reached HKD 152.46 billion in Q3, marking a year-on-year increase of 303.85% [2] Derivatives and Commodity Market - The average daily trading volume for derivatives and commodity contracts maintained positive growth, with a year-on-year increase of 9.28% in Q3 [3] - The average daily trading volume for metal contracts on the London Metal Exchange (LME) reached 71,000 contracts in September, a 5.51% increase year-on-year [3] Interest Rates and Investment Outlook - The Hong Kong Interbank Offered Rate (HIBOR) rebounded in Q3, reaching approximately 3.5% by September 30, which is indicative of a tightening liquidity environment [4] - The sustained high trading activity is expected to continue into Q4, supported by the Federal Reserve's monetary policy shift and ongoing southbound capital inflows [6] Earnings Forecast - The company is projected to achieve Q3 revenue of HKD 7.91 billion, a year-on-year increase of 47.26%, and a net profit of HKD 4.82 billion, up 53.38% year-on-year [5] - Revenue forecasts for 2025, 2026, and 2027 are expected to grow by 27.94%, 5.93%, and 1.17% respectively, indicating a positive growth trajectory [5] Valuation and Investment Recommendation - The current price-to-earnings (PE) ratio for HKEX is 36.49x, which is within a favorable range compared to historical averages [4] - The company maintains a "buy" rating with a target price of HKD 543 per share, supported by strong market activity and valuation advantages [6]

Core Viewpoint - Hong Kong Stock Exchange (HKEX) has announced the establishment of a new subsidiary, Commodity Pricing and Analysis Limited (CPAL), in Dubai, UAE, to enhance its commodity market services [2] Group 1: Company Developments - CPAL will primarily operate pricing management services for the commodity market and provide independent quotes and market analysis for the metals market [2] - The new subsidiary aims to promote the development of the sustainable metal premium business announced by the London Metal Exchange (LME) in April this year [2] Group 2: Strategic Expansion - HKEX intends to expand its commodity business in this strategically important region, facilitating connectivity between the rapidly growing markets of China and the Middle East [2]

香港联交所最新数据显示，10月8日，摩根大通增持香港交易所(00388)28.9039万股，每股作价443.5482 港元，总金额约为1.28亿港元。增持后最新持股数目约为8889.78万股，持股比例为7.01%。 ...

Group 1 - Hong Kong Stock Exchange appointed Hu Zhiheng as Managing Director and Head of Trading Operations, effective October 20, 2025 [1] - Hu Zhiheng previously worked at HSBC as Managing Director and Chief Risk Officer of Global Operations, and has 16 years of experience at JPMorgan, where he rose to Managing Director [3] - Hong Kong Stock Exchange also appointed Guo Hanxiao as Managing Director and Head of Connectivity Business, effective January 1, 2026 [3][4] Group 2 - Guo Hanxiao will lead the newly established connectivity team, overseeing various connectivity projects across asset classes for Hong Kong Stock Exchange [4] - Guo Hanxiao has over 17 years of experience at Hong Kong Stock Exchange and previously worked at UBS, currently serving as Co-Head of Trading [6]